Q1 2022 Results slide image

Q1 2022 Results

Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology KymriahⓇ - CD19 CAR-T Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03570892 BELINDA (CCTL019H2301) 2nd line Diffuse large B-cell lymphoma (DLBCL) Phase 3 318 Event-free Survival (EFS) Tisagenlecleucel versus standard of care Adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline- containing frontline immunochemotherapy Target Patients Read-out Milestone(s) 9 Jul 2021 (actual) Publication Bishop et al at SITC 2019 Abstract submission TBD NCT03876769 CASSIOPEIA (CCTL019G2201J) 1st line high risk acute lymphoblastic leukemia (ALL) Phase 2 160 Disease Free Survival (DFS) Single-arm study of tisagenlecleucel Pediatric and young adult patients with 1st line high risk ALL 2025 TBD 106 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine
View entire presentation